Public Private PartnershipS

TKI-LSH Allowance

LSH-TKI has published a call for the submission of proposals for the TKI allowance. This arrangement is developed to stimulate Public Private Partnerships. Find the call and more information on our website

New LSH-TKI call open!

The basic principle of the TKI-LSH allowance is simple. For every euro that the private sector spends in R&D at a research organization, the TKI receives 25% (TKI base). Herewith, the TKI finances new public-private research. The proposals must meet a few criteria in order to qualify for assessment. The research is in line with the Innovation Contract and the goals of the settlement. 

At least one research organization and entrepreneur carry out a joint project with shared accountability and risk.

​​​One collaborative project can consist of fundamental research, industrial research or experimental development, or a combination of these. All partners in the consortium contribute financially (in cash and/or in kind) and substantially to the project. To see all conditions, we refer you to

If you have any questions about the TKI-LSH call, please contact Laila El Aziz, Program coordinator LSH-TKI, via

With the ending of the FES-funding, the financing of the public-private partnerships via Technological Top Institutes (TTI's) ended. For the transition phase, the Ministry of Economic Affairs reserved a budget of over nine million euros that is distributed by the LSH-TKI. From this transition budget, five million euro’s of subsidies are made available for promising projects from the existing portfolio of the Center of Translational Molecular Medicine (CTMM) and BioMedical Materials (BMM).

The following eleven propositions, the so called ' research pearls'  have been selected:

1. Prostate Cancer Molecular Medicine (PCMM) is searching for new biomarkers (risk indicators) for prostate cancer and developing imaging techniques to screen the effectiveness of treatments.

2. Breast CARE is developing tests and searching for biomarkers that enable better prediction in advance of what combination of drugs has the best chance to kill all cancer cells. 

3. The PREDICCt consortium combines the latest insights into the causes of diabetes mellitus type 2 with innovative techniques to find new biomarkers for the disease and related complications. 

4. INCOAG develops new tests for easily and accurately assessing the risk of thrombosis in patients.

5. COHFAR pursues the great need for the early identification of patients at risk of heart failure or cardiac arrhythmias, as well as improvement of the response to cardiac pacemakers and ICDs.

6. MARS is developing tests that give quick and accurate information about individual patients with sepsis (blood poisoning), which is increasingly common and a major cause of death in hospitals.

7. Within VOLTA new technologies are being developed to treat cancer by using sound waves (high intensity focused ultrasound) and thereby locally heating tumors, enabling treatment of patients without surgery. 

8. BONE IP aims at the development of bone implants with improved biological capacity and thereby enables fast healing of large bone defects and early and durable fixation of bone implants.

9. iValve aims at the development of living, native valves or blood vessels from the patient’s own cell by tissue engineering. 

10. SMARTCARE II aims at structurally strengthening the heart, contributing more effectively to the function of the heart muscle and the fight against heart failure. 

11. TRAMMPOLIN focuses on the design of a new artificial meniscus made from very strong, flexible and durable synthetics.